Website
N/ATelephone
61.8.9329.3396
Address
Unit 4, 117 Broadway Nedlands, Western Australia (WA) 6009
Description
Argenica Therapeutics Ltd. provides neuroprotective treatment. It specializes in development and commercialization of a novel therapeutic known as ARG-007. It offers drug ARG-007 in multiple models of stroke and other central nervous system (CNS) injury models, specifically: stroke including non-human primates; traumatic brain injury; and perinatal hypoxia ischaemia. The company was founded on 20 November 2019 and is headquartered in Nedlands, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.29 - 0.99
Trade Value (12mth)
AU$24,169.00
1 week
-7.19%
1 month
-5.49%
YTD
47.62%
1 year
109.46%
All time high
1.02
EPS 3 yr Growth
957.700%
EBITDA Margin
N/A
Operating Cashflow
-$3m
Free Cash Flow Return
-41.30%
ROIC
-60.30%
Interest Coverage
N/A
Quick Ratio
5.10
Shares on Issue (Fully Dilluted)
99m
HALO Sector
Healthcare
Next Company Report Date
21-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
24 July 24 |
Phase 2 Stroke Clinical Trial Update
×
Phase 2 Stroke Clinical Trial Update |
22 July 24 |
Investor Webinar Presentation
×
Investor Webinar Presentation |
15 July 24 |
Investor Presentation
×
Investor Presentation |
12 July 24 |
Notice of General Meeting/Proxy Form
×
Notice of General Meeting/Proxy Form |
09 July 24 |
Notice of initial substantial holder from IFL
×
Notice of initial substantial holder from IFL |
14 June 24 |
Application for quotation of securities - AGN
×
Application for quotation of securities - AGN |
14 June 24 |
Notification of cessation of securities - AGN
×
Notification of cessation of securities - AGN |
14 June 24 |
Cleansing Notice
×
Cleansing Notice |
12 June 24 |
Notification of cessation of securities - AGN
×
Notification of cessation of securities - AGN |
05 June 24 |
Application for quotation of securities - AGN
×
Application for quotation of securities - AGN |
05 June 24 |
Notification of cessation of securities - AGN
×
Notification of cessation of securities - AGN |
05 June 24 |
Cleansing Notice
×
Cleansing Notice |
05 June 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
05 June 24 |
Non-Executive Director Resignation
×
Non-Executive Director Resignation |
05 June 24 |
Final Director's Interest Notice
×
Final Director's Interest Notice |
15 May 24 |
ARG-007 Reduces Effects of TBI in Preclinical Study
×
ARG-007 Reduces Effects of TBI in Preclinical Study |
29 April 24 |
DSMB Confirms Safety of First Patients Dosed
×
DSMB Confirms Safety of First Patients Dosed |
24 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
22 April 24 |
Application for quotation of securities - AGN
×
Application for quotation of securities - AGN |
22 April 24 |
Cleansing Notice
×
Cleansing Notice |
12 April 24 |
Argenica Successfully Completes $12.0m Placement
×
Argenica Successfully Completes $12.0m Placement |
12 April 24 |
Proposed issue of securities - AGN
×
Proposed issue of securities - AGN |
12 April 24 |
Proposed issue of securities - AGN
×
Proposed issue of securities - AGN |
10 April 24 |
Patient Dosing Milestone Achieved in Phase 2 Stroke Trial
×
Patient Dosing Milestone Achieved in Phase 2 Stroke Trial |
10 April 24 |
Trading Halt
×
Trading Halt |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.